{
  "docId": "019de070-8dac-72dd-8b30-47dcdd26ea78",
  "docSlug": "14b2a339e11f22ed5b817a794c035302",
  "documentTitle": "Chimerix | Mergers and Acquisitions Presentation Deck | 26 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 26,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-8dac-72dd-8b30-47dcdd26ea78/22",
  "deckHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78",
  "deckJsonHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78.json",
  "deckAnchorHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "list",
      "text": "DSTAT development in two therapeutic areas with significant unmet need; Phase 3 front-line AML trial to initiate early this year; Enrolled first cohort in COVID-19 Phase 2 trial – preliminary data expected in 1Q2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bce9390-a2ef-41d5-9ac2-6a2b1fed9580",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "Final steps toward BCV (smallpox) potential commercialization; NDA filed, April 7, 2021 PDUFA date; Satisfies second mandate for 2nd countermeasure for strategic national stockpile; Potential $80-$100m annual cash flow for next 5-12 years",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a5d757b-e8bd-4534-8417-1d2188d3f642",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Synergistic acquisition of precision oncology platform; Potential near-term registration path; Blinded independent central review of ONC201 data in 2021 (recurrent H3 K27M mutant glioma); Opportunities for new indications and pipeline expansion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "734055a4-605d-438d-a121-6bce4db5ec5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Major, near-term paths to value",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f75552c4-8179-4742-a31e-75089f9521e1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a86125ca-2570-4783-b2a8-a9f657627ca1",
      "evidence": "list/bullet: Synergistic acquisition of precision oncology platform; Potential near-term registration path; Blinded independent central review of ONC201 data in 2021 (recurrent H3 K27M mutant glioma); Opportunities for n",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}